Innovation & Tech
Novartis Hit by Triple Clinical Setback as Pipeline Risk Rattles Investors
Novartis shares plunged after del-desiran failed a Phase III trial, compounding setbacks for pelacarsen and rap-cel and raising concerns about the drugmaker’s pipeline as key products face patent pressure.